Integrating CAR T and Bispecific Antibodies in Treatments of Relapsed/Refractory Follicular Lymphoma

Panelists discuss how emerging immunotherapies such as CAR T-cell therapy and bispecific antibodies have transformed treatment for patients whose follicular lymphoma has returned or resisted standard approaches. These options harness the body’s own immune system to recognize and attack malignant cells more precisely. CAR T therapy reprograms a patient’s T cells to target cancer directly, while bispecific antibodies engage both immune and cancer cells to trigger a targeted immune response.

These novel therapies differ in administration and patient experience. CAR T therapy typically involves a one-time infusion after cell collection and modification, while bispecific antibodies are given through repeat infusions in outpatient settings. The timing, eligibility, and logistical considerations of each approach play key roles in treatment planning. Safety monitoring is crucial, as immune activation can lead to inflammatory adverse effects that require careful management.

Panelists discuss how combining and sequencing these therapies may improve long-term control for patients with relapsed or refractory disease. Their integration into the treatment landscape offers new hope, particularly for those who have exhausted traditional options. Ongoing studies aim to clarify optimal timing, safety strategies, and real-world outcomes to ensure these advanced therapies are used safely and effectively for every patient who may benefit.